Cough adverse events and FVC decline in the ATLAS study of inhaled pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis

Authors
Category Primary study
JournalEur. Respir. J.
Year 2024
This article has no abstract
Epistemonikos ID: 3412755a42cb2216816ed42d25e261f071b9cd7d
First added on: Feb 07, 2025